Differential α2‐mediated inhibition of dopamine and noradrenaline release in the parietal and occipital cortex following noradrenaline transporter blockade

Parietal and occipital cortices, while densely innervated by noradrenalin 2 (NA) projections, possess a comparatively sparse dopamine 2 (DA) innervation, even sparser than the prefrontal cortex. We previously reported that reboxetine and desipramine, two selective norepinephrine transporter (NET) blockers, at doses that maximally increase DA in the prefrontal cortex, do not increase DA in the parietal and occipital cortices. In the present study, we performed a full dose–response study of the effect of systemic reboxetine and desipramine on DA and NA in dialysates from the parietal and occipital cortices. Seven doses of reboxetine (0.1, 0.25, 0.5, 1.0, 2.5, 5.0 and 10 mg/kg) and four doses of desipramine (0.25, 1.0, 2.5 and 5.0 mg/kg) were tested. Reboxetine and desipramine differentially affected dialysate DA as compared with NA. Reboxetine increased DA maximally by about 100% after doses of 0.25–0.5 mg/kg and showed a bell‐shaped dose–response function in both areas; desipramine did not affect DA in the parietal cortex and increased it in the occipital cortex only at 2.5 mg/kg. NA was maximally increased by 275% by 0.5–2.5 mg/kg reboxetine and by about 300% by 5.0 mg/kg desipramine with a more linear dose–response curve. The mechanism of peculiar dose–response function of dialysate DA after reboxetine and desipramine was further investigated by testing the effect of drugs on dialysate DA and NA under α2 receptor blockade. Under local perfusion of the occipital cortex with idazoxan, an otherwise ineffective dose of reboxetine and desipramine (5 mg/kg) became effective in raising extracellular DA. In contrast, the effect of reboxetine on NA was potentiated, while that of desipramine was not affected. These results suggest that, in the parietal and occipital cortices, extracellular NA, raised by NET blockade, exerts a preferential inhibitory influence on DA release by acting on local α2 receptors, thus accounting for the bell‐shaped feature of the dose–response function of drugs on dialysate DA in these areas.

[1]  G. Chiara,et al.  Blockade of the Noradrenaline Carrier Increases Extracellular Dopamine Concentrations in the Prefrontal Cortex: Evidence that Dopamine Is Taken up In Vivo by Noradrenergic Terminals , 1990, Journal of neurochemistry.

[2]  L. Pozzi,et al.  Evidence that Extracellular Concentrations of Dopamine Are Regulated by Noradrenergic Neurons in the Frontal Cortex of Rats , 1994, Journal of neurochemistry.

[3]  T. Svensson,et al.  Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortex at the nerve terminal level. , 1999, European journal of pharmacology.

[4]  A. Gobert,et al.  α2‐Adrenergic Receptor Blockade Markedly Potentiates Duloxetine‐ and Fluoxetine‐Induced Increases in Noradrenaline, Dopamine, and Serotonin Levels in the Frontal Cortex of Freely Moving Rats , 1997 .

[5]  T. Svensson,et al.  Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. , 2001, The Journal of pharmacology and experimental therapeutics.

[6]  M. Millan,et al.  Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2‐adrenergic and serotonin2C receptors: a comparison with citalopram , 2000, The European journal of neuroscience.

[7]  T. Svensson,et al.  Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. , 1999, Science.

[8]  R. Wightman,et al.  Catecholamine release and uptake in the mouse prefrontal cortex , 2001, Journal of neurochemistry.

[9]  L. Hein,et al.  Two α2-adrenergic receptor subtypes, α2A and α2C, inhibit transmitter release in the brain of gene-targeted mice , 2002, Neuroscience.

[10]  M. Zigmond,et al.  Local Influence of Endogenous Norepinephrine on Extracellular Dopamine in Rat Medial Prefrontal Cortex , 1995, Journal of neurochemistry.

[11]  D. Wong,et al.  Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex , 2002, Psychopharmacology.

[12]  G. Gessa,et al.  Alpha2‐adrenoceptor mediated co‐release of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex , 2004, Journal of neurochemistry.

[13]  M. Millan,et al.  Buspirone Enhances Duloxetine‐ and Fluoxetine‐Induced Increases in Dialysate Levels of Dopamine and Noradrenaline, but Not Serotonin, in the Frontal Cortex of Freely Moving Rats , 1997, Journal of neurochemistry.

[14]  G. Chiara,et al.  Mianserin markedly and selectively increases extracellular dopamine in the prefrontal cortex as compared to the nucleus accumbens of the rat , 2005, Psychopharmacology.

[15]  G Di Chiara,et al.  A dopamine‐μ1 opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non‐psychostimulant drugs of abuse , 1998, The European journal of neuroscience.

[16]  G. Di Chiara,et al.  Selective serotonin reuptake blockade increases extracellular dopamine in noradrenaline‐rich isocortical but not prefrontal areas: dependence on serotonin‐1A receptors and independence from noradrenergic innervation , 2005, Journal of neurochemistry.

[17]  G. Chiara,et al.  Local 5HT3 receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex , 1995, Psychopharmacology.

[18]  K. Perry,et al.  R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study , 2002, Neuropsychopharmacology.

[19]  G. Chiara,et al.  Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? , 1994, Psychopharmacology.

[20]  K. Starke Presynaptic autoreceptors in the third decade: focus on α2‐adrenoceptors , 2001 .

[21]  G. Di Chiara,et al.  Heterologous monoamine reuptake: lack of transmitter specificity of neuron-specific carriers. , 1992, Neurochemistry international.

[22]  M. Millan The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. , 2004, European journal of pharmacology.

[23]  G. Chiara,et al.  On the preferential release of dopamine in the nucleus accumbens by amphetamine: further evidence obtained by vertically implanted concentric dialysis probes , 2005, Psychopharmacology.

[24]  G. Chiara,et al.  Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine , 2004, Journal of neurochemistry.

[25]  L. Swanson The Rat Brain in Stereotaxic Coordinates, George Paxinos, Charles Watson (Eds.). Academic Press, San Diego, CA (1982), vii + 153, $35.00, ISBN: 0 125 47620 5 , 1984 .

[26]  B. Berger Histochemical identification and localization of dopaminergic axons in rat and human cerebral cortex. , 1977, Advances in biochemical psychopharmacology.

[27]  M. Millan,et al.  The novel monoamine reuptake inhibitor and potential antidepressant, S33005, induces Arc gene expression in cerebral cortex. , 2004, European journal of pharmacology.

[28]  L. Hein,et al.  TWO K 2-ADRENERGIC RECEPTOR SUBTYPES , K 2 A AND K 2 C , INHIBIT TRANSMITTER RELEASE IN THE BRAIN OF GENE-TARGETED MICE , 2002 .

[29]  M. Millan,et al.  Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo , 1998, Neuropharmacology.

[30]  B. Berger,et al.  Dopaminergic innervation of the frontal cerebral cortex. Evolutionary trends and functional implications. , 1992, Advances in neurology.

[31]  R. Wise,et al.  Dopamine Uptake through the Norepinephrine Transporter in Brain Regions with Low Levels of the Dopamine Transporter: Evidence from Knock-Out Mouse Lines , 2002, The Journal of Neuroscience.